AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries.
People today live longer, healthier lives, but along with a longer life expectancy comes a higher prevalence of chronic disease. We take a broad perspective on improving healthcare and are committed to new thinking and approaches; we strive to find new solutions that will enable healthcare systems to bring medical innovation to more patients cost effectively.
We're tackling diseases where there is a significant patient need for more and better solutions, with our focus on hepatitis C, immune-mediated conditions, cancer and more. Our scientists are working to advance a pipeline of specialty medicines that demonstrate both strong clinical performance and economic value. Our expertise in both small molecules and biologics gives us the flexibility to find and pursue the best solution for a given disease.
Our Passion Helps Peopletop
Innovation is the cornerstone of AbbVie’s business as a global biopharmaceutical company. Our focus is on developing medicines that can provide strong clinical performance, measurable patient benefit and economic value, particularly in areas where there is significant need, such as hepatitis C, neuroscience, immunology, oncology, chronic kidney disease and women’s health.
Our Approach to Clinical Trialstop
We are devoted to discovering and developing new medicines. AbbVie's current therapeutic areas of interest are:
- Antiviral (HCV, HIV and RSV)
- Men's Health
- Women's Health
Within each of these therapeutic areas, we have various products in development. The products will change over time as compounds progress through our development program. A critical component of medicinal product development is clinical research, which involves conducting clinical trials in humans to evaluate the safety and efficacy of new products.
For AbbVie's approach to sharing information with regard to its clinical research, see our Postmarketing Commitments.
Partnerships devoted to better outcomestop
AbbVie understands that exceptional partnerships can lead to advances in medicine around the world. AbbVie’s partnerships are dedicated to two important outcomes: delivering innovative new medicines and having an impact on peoples’ lives. Many partnership opportunities are available to our colleagues in healthcare. We partner with the community, government, health care professionals and people living with chronic diseases to advance health care standards and create shared value.
For further information on AbbVie and its people, our portfolio and commitments, please visit www.abbvie.ca and www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.